{"id":"https://openalex.org/W2121001769","doi":"https://doi.org/10.1158/0008-5472.can-04-0673","title":"Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition","display_name":"Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition","alternate_titles":[],"publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2121001769","doi":"https://doi.org/10.1158/0008-5472.can-04-0673","mag":"2121001769","pmid":"https://pubmed.ncbi.nlm.nih.gov/15256463"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.can-04-0673","doi":"https://doi.org/10.1158/0008-5472.can-04-0673","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-04-0673","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2121001769"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108622128","display_name":"Katayoun I. Amiri","orcid":"https://orcid.org/0009-0002-7254-5977","observed_orcids":["https://orcid.org/0009-0002-7254-5977"]},"institutions":[{"id":"https://openalex.org/I118073183","display_name":"Meharry Medical College","ror":"https://ror.org/00k63dq23","country_code":"US","type":"education","lineage":["https://openalex.org/I118073183"]},{"id":"https://openalex.org/I1322918889","display_name":"United States Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889"]},{"id":"https://openalex.org/I2799886695","display_name":"Veterans Health Administration","ror":"https://ror.org/05eq41471","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Katayoun I. Amiri","raw_affiliation_strings":["1Departments of Veterans Affairs; Departments of Cancer Biology and","3Department of Microbiology, Meharry Medical College; and","Departments of Cancer Biology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Departments of Veterans Affairs; Departments of Cancer Biology and","institution_ids":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]},{"raw_affiliation_string":"3Department of Microbiology, Meharry Medical College; and","institution_ids":["https://openalex.org/I118073183"]},{"raw_affiliation_string":"Departments of Cancer Biology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050235861","display_name":"Linda W. Horton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1322918889","display_name":"United States Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889"]},{"id":"https://openalex.org/I2799886695","display_name":"Veterans Health Administration","ror":"https://ror.org/05eq41471","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Linda W. Horton","raw_affiliation_strings":["1Departments of Veterans Affairs; Departments of Cancer Biology and","Departments of Cancer Biology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Departments of Veterans Affairs; Departments of Cancer Biology and","institution_ids":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]},{"raw_affiliation_string":"Departments of Cancer Biology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018589877","display_name":"Bonnie LaFleur","orcid":"https://orcid.org/0000-0002-4939-9337","observed_orcids":["https://orcid.org/0000-0002-4939-9337"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bonnie J. LaFleur","raw_affiliation_strings":["2Biostatistics, Vanderbilt University Medical Center;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Biostatistics, Vanderbilt University Medical Center;","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jeffrey A. Sosman","raw_affiliation_strings":["4Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010542605","display_name":"Ann J. Richmond","orcid":"https://orcid.org/0000-0002-9580-900X","observed_orcids":["https://orcid.org/0000-0002-9580-900X"]},"institutions":[{"id":"https://openalex.org/I1322918889","display_name":"United States Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889"]},{"id":"https://openalex.org/I2799886695","display_name":"Veterans Health Administration","ror":"https://ror.org/05eq41471","country_code":"US","type":"government","lineage":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ann Richmond","raw_affiliation_strings":["1Departments of Veterans Affairs; Departments of Cancer Biology and","Departments of Cancer Biology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Departments of Veterans Affairs; Departments of Cancer Biology and","institution_ids":["https://openalex.org/I1322918889","https://openalex.org/I2799886695"]},{"raw_affiliation_string":"Departments of Cancer Biology and","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.5641,"has_fulltext":false,"cited_by_count":167,"citation_normalized_percentile":{"value":0.96444541,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"64","issue":"14","first_page":"4912","last_page":"4918"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11041","display_name":"Ubiquitin and proteasome pathways","score":0.8964999914169312,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.047600001096725464,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.013100000098347664,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9589999914169312},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9440000057220459},{"id":"https://openalex.org/keywords/proteasome-inhibition","display_name":"proteasome inhibition","score":0.9229999780654907},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/chemosensitization","display_name":"chemosensitization","score":0.8289999961853027},{"id":"https://openalex.org/keywords/nf-kappab","display_name":"NF-\u03baB","score":0.8149999976158142},{"id":"https://openalex.org/keywords/ikappab-degradation","display_name":"I\u03baB degradation","score":0.7450000047683716},{"id":"https://openalex.org/keywords/ubiquitin-proteasome-system","display_name":"ubiquitin-proteasome system","score":0.9850000143051147},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.722000002861023},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.75},{"id":"https://openalex.org/keywords/murine-melanoma-model","display_name":"murine melanoma model","score":0.7580000162124634}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9427070617675781},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.8648473024368286},{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.8504494428634644},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.7778651118278503},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6577943563461304},{"id":"https://openalex.org/C27740335","wikidata":"https://www.wikidata.org/wiki/Q14878333","display_name":"Proteasome","level":2,"score":0.5949668288230896},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5517923831939697},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.524332582950592},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.41801419854164124},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3310876488685608},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25487393140792847},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24291926622390747},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.15034976601600647},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.056578755378723145}],"mesh":[{"descriptor_ui":"D000069286","descriptor_name":"Bortezomib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077204","descriptor_name":"Temozolomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001897","descriptor_name":"Boronic Acids","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002455","descriptor_name":"Cell Division","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000098","qualifier_name":"blood supply","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008807","descriptor_name":"Mice, Inbred BALB C","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009389","descriptor_name":"Neovascularization, Pathologic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015870","descriptor_name":"Gene Expression","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016328","descriptor_name":"NF-kappa B","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D016328","descriptor_name":"NF-kappa B","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D017209","descriptor_name":"Apoptosis","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D021581","descriptor_name":"Active Transport, Cell Nucleus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/0008-5472.can-04-0673","doi":"https://doi.org/10.1158/0008-5472.can-04-0673","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.can-04-0673","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},{"id":"pmid:15256463","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15256463","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1243813451","display_name":null,"funder_award_id":"CA 34590","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G3572849318","display_name":"New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors","funder_award_id":"R01CA116021","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G359867969","display_name":null,"funder_award_id":"IK6 BX005225","funder_id":"https://openalex.org/F4320306127","funder_display_name":"U.S. Department of Veterans Affairs"},{"id":"https://openalex.org/G3809890791","display_name":"Skin Diseases Research Core Center","funder_award_id":"P30AR041943","funder_id":"https://openalex.org/F4320337362","funder_display_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases"},{"id":"https://openalex.org/G7493073135","display_name":"REGULATION OF EXPRESSION OF MGSA/GRO GENES IN MELANOMA","funder_award_id":"R01CA056704","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000880732","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA068485","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320306127","display_name":"U.S. Department of Veterans Affairs","ror":"https://ror.org/05rsv9s98"},{"id":"https://openalex.org/F4320309151","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34"},{"id":"https://openalex.org/F4320320664","display_name":"Durham University","ror":"https://ror.org/01v29qb04"},{"id":"https://openalex.org/F4320333265","display_name":"Takeda Oncology","ror":"https://ror.org/05vm7p871"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337362","display_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","ror":"https://ror.org/006zn3t30"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":53,"referenced_works":["https://openalex.org/W144506950","https://openalex.org/W163149217","https://openalex.org/W1266590697","https://openalex.org/W1481925502","https://openalex.org/W1492381941","https://openalex.org/W1499747652","https://openalex.org/W1502665310","https://openalex.org/W1542257568","https://openalex.org/W1599096704","https://openalex.org/W1950572133","https://openalex.org/W1956288530","https://openalex.org/W1970534746","https://openalex.org/W1983398917","https://openalex.org/W1984993711","https://openalex.org/W1991400488","https://openalex.org/W2003723677","https://openalex.org/W2010755570","https://openalex.org/W2012262605","https://openalex.org/W2022683869","https://openalex.org/W2043385261","https://openalex.org/W2063583488","https://openalex.org/W2064201629","https://openalex.org/W2067465277","https://openalex.org/W2069408580","https://openalex.org/W2073922677","https://openalex.org/W2083308557","https://openalex.org/W2083906562","https://openalex.org/W2102714295","https://openalex.org/W2109694492","https://openalex.org/W2127650036","https://openalex.org/W2131365547","https://openalex.org/W2132195808","https://openalex.org/W2132485651","https://openalex.org/W2143937186","https://openalex.org/W2145727462","https://openalex.org/W2148588230","https://openalex.org/W2150033965","https://openalex.org/W2152929241","https://openalex.org/W2155850284","https://openalex.org/W2159722075","https://openalex.org/W2160345685","https://openalex.org/W2160380481","https://openalex.org/W2166781237","https://openalex.org/W2166994863","https://openalex.org/W2169590701","https://openalex.org/W2171865516","https://openalex.org/W2233087428","https://openalex.org/W2275671604","https://openalex.org/W2315607028","https://openalex.org/W2316434439","https://openalex.org/W2322670200","https://openalex.org/W3192823395","https://openalex.org/W4299437781"],"related_works":["https://openalex.org/W1844018813","https://openalex.org/W2086211787","https://openalex.org/W2117157820","https://openalex.org/W1983732523","https://openalex.org/W1488755767","https://openalex.org/W2131595439","https://openalex.org/W2169933327","https://openalex.org/W2043385261","https://openalex.org/W3010095359","https://openalex.org/W2167361262"],"abstract_inverted_index":{"Melanoma":[0],"poses":[1],"a":[2,86,113],"great":[3],"challenge":[4],"to":[5,16,43,124],"patients,":[6],"oncologists,":[7],"and":[8,53,92],"biologists":[9],"because":[10],"of":[11,35,56,58,80,89,139,146,169],"its":[12],"nearly":[13],"universal":[14],"resistance":[15],"chemotherapy.":[17,44],"Many":[18],"studies":[19],"have":[20],"shown":[21],"that":[22,71,155],"nuclear":[23,59],"factor":[24,46,60],"kappaB":[25,47,61],"is":[26,49],"constitutively":[27],"activated":[28],"in":[29,83,93,132,157],"melanoma,":[30],"thereby":[31],"promoting":[32],"the":[33,40,63,72,78,96,100,167],"proliferation":[34],"melanoma":[36,81,104,126],"cells":[37,82],"by":[38,51,62],"inhibiting":[39],"apoptotic":[41],"responses":[42],"Nuclear":[45],"activity":[48],"regulated":[50],"phosphorylation":[52],"subsequent":[54],"degradation":[55],"inhibitor":[57],"ubiquitin-proteasome":[64],"pathway.":[65],"In":[66],"this":[67],"study,":[68],"we":[69],"show":[70],"novel":[73],"proteasome":[74],"inhibitor,":[75],"bortezomib,":[76],"inhibited":[77],"growth":[79,106,119],"vitro":[84],"at":[85],"concentration":[87],"range":[88],"0.1-10":[90],"nM":[91],"combination":[94,133,158],"with":[95,134,159],"chemotherapeutic":[97,160],"agent":[98],"temozolomide,":[99],"inhibitory":[101],"effect":[102],"on":[103],"cell":[105],"was":[107,122],"even":[108],"more":[109],"prominent.":[110],"Data":[111],"from":[112],"murine":[114],"model":[115],"showed":[116],"reduced":[117],"tumor":[118],"when":[120],"bortezomib":[121,131,156],"administered":[123],"human":[125],"tumors.":[127],"Strikingly,":[128],"animals":[129],"receiving":[130],"temozolomide":[135],"achieved":[136],"complete":[137],"remission":[138],"palpable":[140],"tumors":[141],"after":[142],"only":[143],"30":[144],"days":[145],"therapy,":[147],"lasting":[148],">200":[149],"days.":[150],"Our":[151],"data":[152],"indicate":[153],"strongly":[154],"agents":[161],"should":[162],"be":[163],"studied":[164],"additionally":[165],"for":[166],"treatment":[168],"melanoma.":[170]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2121001769","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
